COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

4.56%

Increased from previous period

Growth of 4.56% while 3141.T shows flat revenue. Bruce Berkowitz would examine growth quality advantage.

Cost of Revenue Growth

5.02%

Increased from previous period

Cost growth of 5.02% while 3141.T maintains flat costs. Bruce Berkowitz would investigate efficiency gap.

Gross Profit Growth

2.69%

Decreased from previous period

Growth of 2.69% while 3141.T shows flat gross profit. Bruce Berkowitz would examine quality advantage.

Gross Margin Ratio Growth

-1.79%

Decreased from previous period

Margin decline while 3141.T shows 0.00% expansion. Joel Greenblatt would examine competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while 3141.T shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while 3141.T shows 0.00% growth. Joel Greenblatt would examine competitive risk.

Other Expenses Growth

265.94%

Increased from previous period

Other expenses change of 265.94% while 3141.T maintains costs. Bruce Berkowitz would investigate efficiency.

Operating Expenses Growth

3.31%

Increased from previous period

Operating expenses change of 3.31% while 3141.T maintains costs. Bruce Berkowitz would investigate control.

Total Costs & Expenses Growth

4.75%

Increased from previous period

Total costs change of 4.75% while 3141.T maintains costs. Bruce Berkowitz would investigate control.

Interest Expense Growth

-6.25%

Decreased from previous period

Interest expense reduction while 3141.T shows 0.00% growth. Joel Greenblatt would examine advantage.

Depreciation & Amortization Growth

16.01%

Increased from previous period

D&A change of 16.01% while 3141.T maintains D&A. Bruce Berkowitz would investigate efficiency.

EBITDA Growth

5.94%

Decreased from previous period

EBITDA change of 5.94% while 3141.T is flat. Bruce Berkowitz would examine quality.

EBITDA Margin Growth

1.32%

Decreased from previous period

Margin change of 1.32% while 3141.T is flat. Bruce Berkowitz would examine quality.

Operating Income Growth

0.67%

Decreased from previous period

Income change of 0.67% while 3141.T is flat. Bruce Berkowitz would examine quality.

Operating Margin Growth

-3.72%

Decreased from previous period

Operating margin decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Other Income/Expenses Growth

86.77%

Increased from previous period

Other expenses change of 86.77% while 3141.T maintains costs. Bruce Berkowitz would investigate control.

Pre-Tax Income Growth

5.98%

Decreased from previous period

Income change of 5.98% while 3141.T is flat. Bruce Berkowitz would examine quality.

Pre-Tax Margin Growth

1.36%

Decreased from previous period

Margin change of 1.36% while 3141.T is flat. Bruce Berkowitz would examine quality.

Income Tax Expense Growth

27.47%

Increased from previous period

Tax expense change of 27.47% while 3141.T maintains burden. Bruce Berkowitz would investigate strategy.

Net Income Growth

-4.69%

Decreased from previous period

Net income decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Net Margin Growth

-8.85%

Decreased from previous period

Net margin decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

EPS Growth

-4.70%

Decreased from previous period

EPS decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Diluted EPS Growth

-4.70%

Decreased from previous period

Diluted EPS decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

4.56%

Increased from previous period

Growth of 4.56% while 3141.T shows flat revenue. Bruce Berkowitz would examine growth quality advantage.

Cost of Revenue Growth

5.02%

Increased from previous period

Cost growth of 5.02% while 3141.T maintains flat costs. Bruce Berkowitz would investigate efficiency gap.

Gross Profit Growth

2.69%

Decreased from previous period

Growth of 2.69% while 3141.T shows flat gross profit. Bruce Berkowitz would examine quality advantage.

Gross Margin Ratio Growth

-1.79%

Decreased from previous period

Margin decline while 3141.T shows 0.00% expansion. Joel Greenblatt would examine competitive position.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while 3141.T shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while 3141.T shows 0.00% growth. Joel Greenblatt would examine competitive risk.

Other Expenses Growth

265.94%

Increased from previous period

Other expenses change of 265.94% while 3141.T maintains costs. Bruce Berkowitz would investigate efficiency.

Operating Expenses Growth

3.31%

Increased from previous period

Operating expenses change of 3.31% while 3141.T maintains costs. Bruce Berkowitz would investigate control.

Total Costs & Expenses Growth

4.75%

Increased from previous period

Total costs change of 4.75% while 3141.T maintains costs. Bruce Berkowitz would investigate control.

Interest Expense Growth

-6.25%

Decreased from previous period

Interest expense reduction while 3141.T shows 0.00% growth. Joel Greenblatt would examine advantage.

Depreciation & Amortization Growth

16.01%

Increased from previous period

D&A change of 16.01% while 3141.T maintains D&A. Bruce Berkowitz would investigate efficiency.

EBITDA Growth

5.94%

Decreased from previous period

EBITDA change of 5.94% while 3141.T is flat. Bruce Berkowitz would examine quality.

EBITDA Margin Growth

1.32%

Decreased from previous period

Margin change of 1.32% while 3141.T is flat. Bruce Berkowitz would examine quality.

Operating Income Growth

0.67%

Decreased from previous period

Income change of 0.67% while 3141.T is flat. Bruce Berkowitz would examine quality.

Operating Margin Growth

-3.72%

Decreased from previous period

Operating margin decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Other Income/Expenses Growth

86.77%

Increased from previous period

Other expenses change of 86.77% while 3141.T maintains costs. Bruce Berkowitz would investigate control.

Pre-Tax Income Growth

5.98%

Decreased from previous period

Income change of 5.98% while 3141.T is flat. Bruce Berkowitz would examine quality.

Pre-Tax Margin Growth

1.36%

Decreased from previous period

Margin change of 1.36% while 3141.T is flat. Bruce Berkowitz would examine quality.

Income Tax Expense Growth

27.47%

Increased from previous period

Tax expense change of 27.47% while 3141.T maintains burden. Bruce Berkowitz would investigate strategy.

Net Income Growth

-4.69%

Decreased from previous period

Net income decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Net Margin Growth

-8.85%

Decreased from previous period

Net margin decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

EPS Growth

-4.70%

Decreased from previous period

EPS decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Diluted EPS Growth

-4.70%

Decreased from previous period

Diluted EPS decline while 3141.T shows 0.00% growth. Joel Greenblatt would examine position.

Share Count Growth (Basic)

No Data

No Data available this quarter, please select a different quarter.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: